FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6414-6424

  Patil, Abhijit A ^a   Sayal, Parag ^b   Depondt, Marie Lise ^a   Beveridge, Ryan D ^a   Roylance, Anthony ^b   Kriplani, Deepti H ^a   Myers, Katie N ^a   Cox, Angela ^a   Jellinek, David ^b   Fernando, Malee ^b   Carroll, Thomas A ^b   Collis, Spencer J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Chemo sensitisation; Fanconi anaemia; Glioblastoma; Glioma; Temozolomide

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; ANTINEOPLASTIC AGENT; CARMUSTINE; CURCUMIN; FANCONI ANEMIA GROUP D2 PROTEIN; MENADIONE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; FANCD2 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; DRUG SENSITIVITY; FANCONI ANEMIA PATHWAY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HUMAN TISSUE; NEURILEMOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; FANCONI ANEMIA; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; CURCUMIN; DACARBAZINE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; GLIOMA; HUMANS; NEOPLASM GRADING;

EID: 84906261175     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2225     Document Type: Article

References (30)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK and Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert opinion on investigational drugs. 2009; 18(8):1061-1083.
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
3. Johannessen TC, Bjerkvig R and Tysnes BB. DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? Cancer treatment reviews. 2008; 34(6):558-567.
4. Crossan GP and Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. The Journal of pathology. 2012; 226(2):326-337.
5. Kim H and D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes & development. 2012; 26(13):1393-1408.
6. Kupfer GM. Fanconi anemia: a signal transduction and DNA repair pathway. The Yale journal of biology and medicine. 2013; 86(4):491-497.
7. Schlacher K, Wu H and Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer cell. 2012; 22(1):106-116.
8. Lu WT, Lemonidis K, Drayton RM and Nouspikel T. The Fanconi anemia pathway is downregulated upon macrophage differentiation through two distinct mechanisms. Cell cycle. 2011; 10(19):3300-3310.
9. Holzel M, van Diest PJ, Bier P, Wallisch M, Hoatlin ME, Joenje H and de Winter JP. FANCD2 protein is expressed in proliferating cells of human tissues that are cancerprone in Fanconi anaemia. The Journal of pathology. 2003; 201(2):198-203.
10. van de Vrugt HJ, Cheng NC, de Vries Y, Rooimans MA, de Groot J, Scheper RJ, Zhi Y, Hoatlin ME, Joenje H and Arwert F. Cloning and characterization of murine fanconi anemia group A gene: Fanca protein is expressed in lymphoid tissues, testis, and ovary. Mammalian genome: official journal of the International Mammalian Genome Society. 2000; 11(4):326-331.
11. Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomaki V, Valo E, Nunez-Fontarnau J, Rantanen V, Karinen S, Nousiainen K, Lahesmaa-Korpinen AM, Miettinen M, Saarinen L, Kohonen P, Wu J, et al. Largescale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome medicine. 2010; 2(9):65.
12. Kee Y and D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes & development. 2010; 24(16):1680-1694.
13. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV and D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Molecular cancer therapeutics. 2006; 5(4):952-961.
14. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE and Kern SE. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer research. 2007; 67(5):2169-2177.
15. Landais I, Hiddingh S, McCarroll M, Yang C, Sun A, Turker MS, Snyder JP and Hoatlin ME. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Molecular cancer. 2009; 8:133.
16. Landais I, Sobeck A, Stone S, LaChapelle A and Hoatlin ME. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. International journal of cancer Journal international du cancer. 2009; 124(4):783-792.
17. Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A and Kohno T. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Carcinogenesis. 2013.
18. Chen CC, Taniguchi T and D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. Journal of molecular medicine. 2007; 85(5):497-509.
19. Kondo N, Takahashi A, Mori E, Noda T, Zdzienicka MZ, Thompson LH, Helleday T, Suzuki M, Kinashi Y, Masunaga S, Ono K, Hasegawa M and Ohnishi T. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PloS one. 2011; 6(5):e19659.
20. Jacquemont C, Simon JA, D'Andrea AD and Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Molecular cancer. 2012; 11:26.
21. Fael Al-Mayhani TM, Ball SL, Zhao JW, Fawcett J, Ichimura K, Collins PV and Watts C. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. Journal of neuroscience methods. 2009; 176(2):192-199.
22. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A and Dirks P. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell stem cell. 2009; 4(6):568-580.
23. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M and D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Molecular cell. 2001; 7(2):249-262.
24. Jun DW, Hwang M, Kim HJ, Hwang SK, Kim S and Lee CH. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PloS one. 2013; 8(10):e75905.
25. Bar-Sela G, Epelbaum R and Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Current medicinal chemistry. 2010; 17(3):190-197.
26. Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, Winstanley JH, Barraclough DL, Barraclough R, West CR and Jones NJ. Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol. 2010; 176(6):2935-2947.
27. Dilnawaz F and Sahoo SK. Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2013; 85(3 Pt A):452-462.
28. Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, Clark SK, Britton RG, Jones DJ, Scott EN, Berry DP, Hemingway D, Miller AS, Brown K, Gescher AJ and Steward WP. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability. Cancer prevention research. 2013; 6(2):119-128.
29. Debinski W and Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert review of neurotherapeutics. 2009; 9(10):1519-1527.
30. Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD and Boulton SJ. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nature cell biology. 2007; 9(4):391-401.